Difficulty: Medium
Average Score: 86%
Practice
Lidocaine is the preferred antiarrhythmic for emergency control of cardiac arrhythmias following acute myocardial infarction because
Correct answer
D
Rationale
In the context of managing cardiac arrhythmias following an acute myocardial infarction, Lidocaine is the preferred antiarrhythmic due to its unique properties. Option D, stating that Lidocaine has both rapidly developing and titratable antiarrhythmic action, as well as causing little myocardial depression and hypotension, is correct.
Lidocaine's rapid onset of action allows for quick control of arrhythmias in emergency situations, crucial for post-myocardial infarction cases where time is of the essence. Additionally, its titratability enables healthcare providers to adjust the dose based on the patient's response, ensuring optimal therapeutic effects while minimizing adverse reactions.
Options A, B, and C are incorrect for various reasons. Option A is partially correct but does not address Lidocaine's advantage of causing minimal myocardial depression and hypotension, which is crucial in the context of post-myocardial infarction patients who may already have compromised cardiac function. Option B is incorrect because Lidocaine, unlike other antiarrhythmics, does not typically cause significant myocardial depression or hypotension, making it safer in this setting. Option C is incorrect as Lidocaine is more effective in ventricular arrhythmias rather than atrial ones.
In an educational context, understanding the rationale behind choosing specific drugs in different clinical scenarios is essential for healthcare professionals. Knowing the properties of Lidocaine and its suitability for managing post-myocardial infarction arrhythmias can improve patient outcomes and safety in emergency situations. This knowledge underscores the importance of evidence-based practice and individualizing treatment to each patient's needs.
Lidocaine's rapid onset of action allows for quick control of arrhythmias in emergency situations, crucial for post-myocardial infarction cases where time is of the essence. Additionally, its titratability enables healthcare providers to adjust the dose based on the patient's response, ensuring optimal therapeutic effects while minimizing adverse reactions.
Options A, B, and C are incorrect for various reasons. Option A is partially correct but does not address Lidocaine's advantage of causing minimal myocardial depression and hypotension, which is crucial in the context of post-myocardial infarction patients who may already have compromised cardiac function. Option B is incorrect because Lidocaine, unlike other antiarrhythmics, does not typically cause significant myocardial depression or hypotension, making it safer in this setting. Option C is incorrect as Lidocaine is more effective in ventricular arrhythmias rather than atrial ones.
In an educational context, understanding the rationale behind choosing specific drugs in different clinical scenarios is essential for healthcare professionals. Knowing the properties of Lidocaine and its suitability for managing post-myocardial infarction arrhythmias can improve patient outcomes and safety in emergency situations. This knowledge underscores the importance of evidence-based practice and individualizing treatment to each patient's needs.